Health Technology · Pharmaceuticals: Major · NSE: HESTERBIO · data 2026-10-09
Hester Biosciences Limited
Health check: Strong (7.8/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹2,058.7
Market cap
₹1,748 cr
P/E
12.9
P/B
—
ROE
16.5%
ROCE
13.0%
Debt / equity
0.54
Dividend yield
0.54%
1-year return
16.4%
52-week high
₹2,683.6
52-week low
₹1,239.3
Operating margin
19.9%
Growth
| Revenue (last 12 months) | ₹326 cr |
| Net profit (last 12 months) | ₹136 cr |
| Sales growth, 3 years (yearly) | 7.7% |
| Profit growth, 3 years (yearly) | 27.8% |
Chart patterns
- Double top — breakdown (key level ₹2,146)
Similar companies
Panacea Biotec Limited (PANACEABIO) · Beta Drugs Ltd. (BETA) · Windlas Biotech Ltd. (WINDLAS) · NGL Fine-Chem Ltd. (NGLFINE) · Accent Microcell Limited (ACCENTMIC)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open HESTERBIO in NSE Scanner →